Finance coverage highlighted that Ambrosia and Syneron are moving toward the clinic with nine-digit Series B rounds, according to the sourced financing report. The recap places the deals alongside other sector capital events mentioned in the same piece, including an IPO filing reference (Kailera), and additional funding and follow-on activity noted in the report. For biotech teams, late-stage preclinical-to-clinic funding is a critical liquidity milestone that can accelerate lead optimization, IND-enabling work, and early clinical operations. The near-term watch will be whether the companies can translate platform progress into clear clinical entry plans using the new capital.